Lactobacillus Gasseri: Uses, Side Effects, and More

Lactobacillus gasseri is a lactic acid-producing bacterium naturally found in the human gut, mouth, and vaginal tract. Among the hundreds of probiotic strains available in supplements, L. gasseri has attracted outsized research interest for its effects on body composition, digestive health, and vaginal flora balance.

So what is L. gasseri, and why does it keep showing up in clinical research? Unlike many probiotic strains marketed on name recognition alone, L. gasseri has strain-specific data from randomized, placebo-controlled human trials demonstrating measurable effects on visceral fat, immune markers, and vaginal microbiome composition. Here is what the evidence says about the benefits of L. gasseri, where the limitations lie, and how to think about this gasseri probiotic in the context of a broader wellness strategy.

Key Benefits of L. Gasseri Backed by Clinical Research

L. gasseri has been studied across several health outcomes, with the strongest evidence concentrated in body composition, digestive comfort, and women's health. Each benefit below is supported by peer-reviewed human research.

Reduces Visceral Fat and Supports Body Composition

The most cited research on the benefits of L. gasseri involves its effects on abdominal fat. A landmark 2013 randomized, double-blind, placebo-controlled trial published in the British Journal of Nutrition followed 210 healthy Japanese adults with elevated visceral fat for 12 weeks. Participants consuming fermented milk containing L. gasseri SBT2055 showed an average 8.5% reduction in visceral fat area, along with significant decreases in BMI, waist circumference, hip circumference, and body fat mass [1].

An earlier 2010 trial by the same research group (n=87) confirmed these findings, showing a 4.6% decrease in visceral fat and a 1.4% decrease in body weight over the same 12-week period [2].

Two important details that often get lost in marketing claims:

• The daily dose in the 2013 trial was approximately 200 million to 2 billion CFU, far lower than the 10 billion+ CFU often cited in supplement advertising. Higher doses were not shown to be more effective.

• The effects reversed within four weeks after participants stopped taking the supplement, meaning consistent, ongoing use is necessary to maintain results [1].

The proposed mechanism involves L. gasseri's ability to enlarge fat emulsion droplets in the gut, which reduces the surface area available for digestive enzymes to break down dietary fat. A 2015 study confirmed that this leads to increased fecal fat excretion, meaning the body absorbs less fat from food [3].

For those interested in body composition support, L. gasseri represents one piece of a multi-pathway approach to metabolic health.

Supports Digestive Comfort and IBS Symptoms

L. gasseri has shown benefits for digestive health beyond its effects on fat metabolism. Clinical research has demonstrated positive effects on irritable bowel syndrome (IBS) severity scores, with participants reporting improvements in abdominal pain, bloating, and bowel regularity compared to placebo groups.

As a lactic acid-producing bacterium, L. gasseri helps maintain an acidic gut environment that discourages the growth of harmful bacteria while supporting the conditions beneficial microbes need to thrive. Maintaining a balanced gut ecosystem is foundational for digestive comfort, nutrient absorption, and immune regulation.

Comprehensive gut health support often works best when multiple approaches, including prebiotics, postbiotics, and targeted probiotics like the strains in VZen, work together to maintain microbiome integrity.

Supports Vaginal Microbiome Balance

L. gasseri is one of several Lactobacillus species naturally present in a healthy vaginal microbiome. A 2023 randomized controlled trial published in Frontiers in Immunology tested oral administration of L. gasseri TM13 combined with L. crispatus in women recovering from bacterial vaginosis (BV). Participants in the probiotic group showed significantly improved vaginal health markers, reduced pathogenic bacteria, and restored Lactobacillus dominance compared to the antibiotic-only group [4].

A 2025 study published in Microbiology Spectrum confirmed that orally administered L. gasseri successfully colonizes the vaginal tract in healthy women, validating the oral-to-vaginal migration pathway that makes oral probiotic supplementation relevant for vaginal health [5].

Zenos VZen includes Lactobacillus gasseri as one of four clinically studied probiotic strains in its formulation, alongside Lactobacillus rhamnosus, Saccharomyces boulardii, and DE111® Bacillus subtilis. Combined with PaCran® Cranberry (250 mg) for urinary tract defense and PreforPro® (15 mg) bacteriophages, VZen delivers L. gasseri as part of a multi-strain approach to vaginal and urinary health.

Supports Immune Function

L. gasseri produces lactic acid and other antimicrobial compounds that help the immune system by maintaining microbial balance in the gut and vaginal tract. Clinical research suggests that L. gasseri supplementation modulates inflammatory markers and supports the body's natural defense mechanisms.

A healthy gut microbiome, where beneficial bacteria like L. gasseri hold adequate territory, helps train and regulate immune responses. When pathogenic bacteria gain ground, immune function becomes less efficient, and chronic low-grade inflammation often follows.

May Help Reduce Cholesterol

Preliminary research has linked certain L. gasseri strains to modest reductions in total cholesterol and LDL cholesterol levels. While this evidence is still emerging and not as robust as the body composition or vaginal health data, the proposed mechanism involves L. gasseri's interaction with bile salts in the gut, which can influence cholesterol metabolism.

More large-scale human trials are needed before cholesterol reduction can be considered a confirmed benefit of L. gasseri supplementation.

Side Effects and Safety

L. gasseri has a strong safety profile in clinical research. Side effects reported in trials are generally mild and may include:

• Temporary bloating or gas during the first few days as the gut microbiome adjusts

• Mild digestive discomfort, which typically resolves within a week

• Rare allergic reactions in individuals sensitive to dairy-based probiotic delivery systems

People with compromised immune systems or those undergoing immunosuppressive treatment should consult a healthcare provider before starting any probiotic supplement. For the general population, L. gasseri is well tolerated at the doses used in clinical trials.

How to Choose a Quality L. Gasseri Supplement

Not all gasseri probiotic products are formulated equally. When evaluating options, keep these factors in mind:

• Strain specificity matters. "Lactobacillus gasseri" alone is insufficient. The clinical trials used named strains like SBT2055 and BNR17. A quality supplement identifies the exact strain on the label.

• Dose should align with the research. The visceral fat trials used approximately 200 million to 2 billion CFU daily, not the inflated counts often seen in marketing [1].

• Viability through digestion is essential. Probiotic bacteria must survive stomach acid to reach the gut alive. Look for supplements with acid-resistant delivery systems or strains with documented survivability.

Where It All Adds Up

L. gasseri is one of the more clinically substantiated probiotic strains available, with human trial data supporting benefits for body composition, digestive comfort, vaginal microbiome balance, and immune function. The research is strongest for visceral fat reduction and vaginal health restoration, with emerging evidence for cholesterol and broader metabolic effects.

Zenos VZen includes Lactobacillus gasseri alongside L. rhamnosus, Saccharomyces boulardii, DE111®, PaCran® Cranberry, and PreforPro® bacteriophages in a formula designed for comprehensive female vaginal, urinary, and gut health. If the vaginal microbiome and urinary tract benefits of L. gasseri resonate with your health goals, VZen delivers this strain as part of a multi-pathway approach backed by clinical research.

Browse Our Collection →

Frequently Asked Questions